클라미디아 감염 진단 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Chlamydia Infection Diagnostics Market was valued at USD 1.5 billion in 2023. Projections indicate a growth trajectory, with an anticipated CAGR of 7.1% from 2024 to 2032, driven by technological advancements, heightened awareness, and shifting healthcare demands.

Point-of-care (POC) tests are pivotal in detecting Chlamydia trachomatis, boasting high sensitivity and specificity. The shift towards molecular diagnostics underscores the demand for precise and timely infection identification, reducing complications and transmission risks.

There's a rising trend in home-based testing kits due to patients' preference for convenience and privacy. Innovations like multiplex assays, which enable simultaneous detection of multiple sexually transmitted infections (STIs), are becoming popular for their efficiency and cost-effectiveness. Public health campaigns and educational initiatives boost awareness and promote regular screenings, further propelling market growth.

Government initiatives also bolster market expansion. For instance, in June 2021, the U.K. government spotlighted women in its National Chlamydia Screening Programme (NCSP), recognizing their heightened risk of severe infection outcomes. This move aims to fast-track treatment and expand community testing for sexually active women under 25.

The overall Chlamydia infection diagnostics industry is classified based on test type, type of infections, end-use, and region.

In 2023, the nucleic acid amplification test (NAAT) segment led the market, generating approximately USD 668.3 million in revenues, owing to their unmatched sensitivity and specificity. Their capability to detect minimal Chlamydia trachomatis DNA levels ensures accurate infection identification. This accuracy diminishes false negatives, guaranteeing more dependable diagnoses. Given that many chlamydia infections, especially in women, are asymptomatic, NAATs' ability to pinpoint these cases is vital for early intervention, preventing complications like pelvic inflammatory disease and infertility. NAATs deliver swift results, often within hours, crucial for prompt diagnosis and treatment. This rapidity enhances patient management and curtails infection spread.

In 2023, hospitals emerged as the dominant segment in the market, with projections indicating a robust growth rate of 7.4% during the forecast period. Equipped with cutting-edge diagnostic technologies and laboratories, hospitals can conduct a diverse array of tests, including NAATs and other molecular diagnostics. This comprehensive infrastructure empowers hospitals to deliver precise and efficient chlamydia testing, solidifying their market prominence. With a high patient turnover, including those with STI symptoms or routine screenings, hospitals' robust diagnostic capabilities position them as primary users of chlamydia diagnostics. Offering an all-encompassing approach-diagnosis, treatment, and follow-up-hospitals enhance patient convenience and ensure care continuity, making them the preferred venue for chlamydia testing.

In 2023, North America accounted for a revenue of USD 588.1 million in the chlamydia infection diagnostics market, with expectations of significant growth in the coming years. The U.S., in particular, grapples with one of the world's highest chlamydia infection rates, spurring a demand for effective diagnostic solutions. Organizations like the CDC champion regular screenings and early chlamydia detection. Their initiatives, from routine screenings for those under 25 to targeted programs for high-risk groups, amplify the demand for diagnostic tests. Heightened awareness and education surrounding STIs and their health ramifications, bolstered by campaigns emphasizing the significance of STI testing and modern diagnostic tools, are driving up testing rates and fueling market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of chlamydia infections
    • 3.2.1.2 Advancements in diagnostic technologies
    • 3.2.1.3 Growing adoption of home testing kits
    • 3.2.1.4 Increase in government initiatives and funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of awareness in low and middle-income countries
    • 3.2.2.2 Social stigma and confidentiality concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Technological landscape
• 3.7 Porter's analysis
• 3.8 PESTEL analysis
• 3.9 Gap analysis
• 3.10 Product pipeline analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis, 2023
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Nucleic acid amplification test (NAAT)
• 5.3 Serology test
• 5.4 Direct fluorescent antibody test
• 5.5 Culture test
• 5.6 Other test types

Chapter 6 Market Estimates and Forecast, By Type of Infections, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Genital chlamydia infection
• 6.3 Rectal chlamydia infection
• 6.4 Ocular chlamydia infection

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Specialty clinics
• 7.4 Diagnostic centres

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott
• 9.2 BD
• 9.3 Bio-Rad Laboratories, Inc.
• 9.4 DiaSorin S.p.A.
• 9.5 F. Hoffmann-La Roche Ltd
• 9.6 Hologic, Inc.
• 9.7 QuidelOrtho Corporation.
• 9.8 Siemens Healthineers
• 9.9 Thermo Fisher Scientific Inc.
• 9.10 Trinity Biotech Plc.